Paper Details

  1. Home
  2. Paper Details

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

Author: CarrA, CooperD A, KelleherA D, ZaundersJ

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Ritonavir, an HIV-1 protease inhibitor, significantly increased CD4 and CD8 lymphocyte counts and improved immune function in 21 patients.
Paper Details　
Original Abstract of the Article :
Effects of a human immunodeficiency virus (HIV) type 1 protease inhibitor, ritonavir, were evaluated in 21 patients enrolled in a phase I/II study. The magnitude and rates of CD4 and CD8 lymphocyte increase, changes in subsets of CD4 and CD8 lymphocytes, and proliferative responses to mitogen and an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/173.2.321

データ提供：米国国立医学図書館（NLM）

Ritonavir's Impact on Immune Response in HIV-Infected Individuals

The study investigates the effects of [ritonavir], an [HIV-specific protease inhibitor], on the [immune response] of [HIV-infected individuals]. The researchers analyzed changes in [CD4 and CD8 lymphocyte counts] and [proliferative responses] to [mitogen and antigens] in patients receiving [ritonavir treatment]. They found that [ritonavir treatment] led to significant increases in both [CD4 and CD8 lymphocyte counts] and improvements in [lymphocyte function], suggesting a positive impact on the [immune system] of [HIV-infected individuals].

Boosting Immune Response in HIV-Infected Individuals

This research provides evidence for the potential of [ritonavir] to enhance the [immune response] in [HIV-infected individuals]. The study's findings demonstrate that [ritonavir treatment] can lead to significant increases in [CD4 and CD8 lymphocyte counts] and improvements in [lymphocyte function], suggesting a potential role for [ritonavir] in managing the [immune system] of [HIV-infected individuals].

Hope for HIV-Infected Individuals

This research offers a glimmer of hope for [HIV-infected individuals] by highlighting the potential of [ritonavir] to bolster the [immune system]. The study's findings suggest that [ritonavir treatment] can lead to a more robust [immune response], paving the way for improved health outcomes. Like the resilient life that thrives in a harsh desert, this research demonstrates the remarkable ability of the human body to overcome challenges, even in the face of adversity.

Dr.Camel's Conclusion

This study demonstrates the positive impact of [ritonavir] on the [immune response] of [HIV-infected individuals]. The research highlights the importance of [protease inhibitors] in managing [HIV infection] and underscores the potential for ongoing research to further improve treatment outcomes. This research reminds us that, like a desert that can bloom with life after a rainstorm, even in the face of adversity, there is hope for healing and recovery.

Date :
  1. Date Completed 1996-03-05
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

8568292

DOI: Digital Object Identifier

10.1093/infdis/173.2.321

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.